
    
      The duration of the study will be 6 years from the date the first patient enters the study.
      Each patient will continue with the study until the patient withdraws, the Investigator
      withdraws the patient, or the Sponsor terminates the study.

      An additional follow-up phase will begin after the patient's last planned visit in the 6-year
      study and last until avalglucosidase alfa is approved in the patient's country for all
      patients.
    
  